Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Terns Pharmaceuticals, Inc. (TERN) had Return on Tangible Equity of -9.56% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-96.21M |
|
-- |
|
-- |
|
$110.12M |
|
$-110.12M |
|
$14.50M |
|
$-95.63M |
|
$-95.63M |
|
$-96.21M |
|
$-96.21M |
|
$-96.21M |
|
$-96.21M |
|
$-110.12M |
|
$-109.68M |
|
93.17M |
|
93.17M |
|
$-1.03 |
|
$-1.03 |
|
| Balance Sheet Financials | |
$1.02B |
|
$0.05M |
|
$0.88M |
|
$1.03B |
|
$16.41M |
|
-- |
|
$2.14M |
|
$18.55M |
|
$1.01B |
|
$1.01B |
|
$1.01B |
|
112.33M |
|
| Cash Flow Statement Financials | |
$-82.18M |
|
$-298.04M |
|
$743.51M |
|
$161.44M |
|
$524.75M |
|
$363.31M |
|
$13.40M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
62.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-82.18M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.56% |
|
|
Return on Tangible Equity |
-9.56% |
-9.39% |
|
-9.56% |
|
$8.96 |
|
$-0.88 |
|
$-0.88 |
|